Document Detail


Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large U.S. cohort.
MedLine Citation:
PMID:  21954144     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To examine the threshold in disease activity associated with switching biologic treatment regimens in rheumatoid arthritis (RA) patients in real-world clinical practice.
METHODS: Using data from a prospective observational North American cohort of RA patients through December 30, 2009, patients who initiated a new anti-tumor necrosis factor α (anti-TNFα) agent with ≥6 months of followup were identified. Patients were classified as switchers or maintainers depending on whether they continued their anti-TNF treatment or switched (including discontinuation) within 12 months. Level of disease activity measured by the Clinical Disease Activity Index (CDAI) and Disease Activity Score in 28 joints (DAS28) at the time of the switch (corresponding followup visit for maintainers) was examined and random-effect multivariable logistic regression was used to adjust for covariates.
RESULTS: Mean age and RA duration among 1,549 eligible patients were 56.1 and 9.6 years, respectively, 80% were women, 62% were initiating their first biologic, and 30% were initiating their second biologic. At the time of the switch, the median DAS28 and CDAI score were 3.1 and 8.4 among maintainers and 4.0 and 15.2 among switchers, respectively. Maintainers also experienced a greater amount of reduction in disease activity compared with switchers (CDAI: -7.7 versus -2.3, DAS28: -1.1 versus -0.3). The threshold to switch decreased over calendar time, with the greatest amount of reduction observed among patients with moderate disease activity.
CONCLUSION: On average, physicians and patients were willing to continue biologic treatment for patients who were at or near low disease activity. The threshold to switch decreased over time, especially among partial responders.
Authors:
Jie Zhang; Ying Shan; George Reed; Joel Kremer; Jeffrey D Greenberg; Scott Baumgartner; Jeffrey R Curtis
Related Documents :
15811244 - Revisiting previously searched locations in visual neglect: role of right parietal and ...
19440714 - Incomplete hippocampal inversion-is there a relation to epilepsy?
19279504 - Source localization of temporal lobe epilepsy using pca-loreta analysis on ictal eeg re...
8060424 - Corpus callosum agenesis and epilepsy: pet findings.
21060664 - Spectral domain optical coherence tomography as an effective screening test for hydroxy...
19051494 - Clinical, radiologic, and histopathologic studies on pulmonary toxicity induced by trea...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Arthritis care & research     Volume:  63     ISSN:  2151-4658     ISO Abbreviation:  Arthritis Care Res (Hoboken)     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-11-30     Completed Date:  2012-01-17     Revised Date:  2013-06-27    
Medline Journal Info:
Nlm Unique ID:  101518086     Medline TA:  Arthritis Care Res (Hoboken)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1672-9     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 by the American College of Rheumatology.
Affiliation:
University of Alabama at Birmingham, 35294, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antirheumatic Agents / therapeutic use*
Arthritis, Rheumatoid / diagnosis,  drug therapy*,  immunology
Biological Agents / therapeutic use*
Drug Substitution*
Female
Humans
Logistic Models
Male
Middle Aged
Predictive Value of Tests
Prospective Studies
Questionnaires
Registries
Severity of Illness Index
Time Factors
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
United States
Grant Support
ID/Acronym/Agency:
AR053351/AR/NIAMS NIH HHS; K23 AR053351-04/AR/NIAMS NIH HHS; K23AR054412/AR/NIAMS NIH HHS; R01HS018517/HS/AHRQ HHS; T32HS013852/HS/AHRQ HHS
Chemical
Reg. No./Substance:
0/Antirheumatic Agents; 0/Biological Agents; 0/Tumor Necrosis Factor-alpha
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  From Micro to Macro: Access to Long-Range Li(+) Diffusion Parameters in Solids via Microscopic (6,?...
Next Document:  Intracardiac echocardiography and fluoroscopy guided percutaneous left ventricular pseudoaneurysm cl...